Turku, Finland – 18 December 2018: DelSiTech Ltd, a Finnish drug delivery technology and drug development company and Innovare R&D, a leading Mexican pharmaceutical company, have signed a world-wide, exclusive licence agreement for the use of DelSiTech’s Silica Matrix drug delivery platform in the development and commercialisation of a long acting HIV therapy. Read more
Receives First Milestone Payment for NXP001 Cambridge, UK, 27 November 2018: Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces it has expanded its licensing agreement with Newsummit Biopharma (“NSB”), its Chinese licensing partner for NXP001, which is in development for cancer supportive care. Read […]
Venture fund focuses on supporting early stage healthcare and tech companies 27 November 2018, Amsterdam: INKEF Capital (INKEF), the Dutch venture capital fund focused on technology and healthcare, announces the appointment of Roel Bulthuis as Managing Director and Head of Healthcare Team. He will co-manage the INKEF fund alongside Robert Jan Galema, Head of Technology […]
